Jaguar Health Announces Promising Crofelemer Trial Results

Jaguar Animal Health ( (JAGX) ) has shared an announcement.

On April 30, 2025, Jaguar Health announced promising initial results from a proof-of-concept trial of crofelemer, a novel liquid formulation aimed at reducing the need for total parenteral nutrition (TPN) in patients with microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF). The trial demonstrated that crofelemer reduced TPN requirements by up to 27% and 12.5% for MVID and SBS-IF patients, respectively, and showed potential for improving nutrient absorption and quality of life. These findings may support crofelemer’s inclusion in expedited regulatory programs in the EU and US, highlighting its potential as a novel therapeutic option for these rare conditions.

Spark’s Take on JAGX Stock

According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.

Jaguar Animal Health’s stock score is notably low, primarily due to substantial financial challenges, including high leverage and negative profitability. Technical analysis indicates bearish trends, while valuation metrics are unappealing. Although earnings calls and corporate events offer some optimism with revenue growth and potential regulatory advancements, persistent net losses and clinical trial challenges continue to weigh heavily on the stock’s potential.

To see Spark’s full report on JAGX stock, click here.

More about Jaguar Animal Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company specializing in developing novel proprietary prescription medicines derived from plants in rainforest areas. The company focuses on addressing gastrointestinal distress, particularly symptoms like chronic diarrhea and bowel incontinence. Jaguar’s family companies, Napo Pharmaceuticals and Napo Therapeutics, are dedicated to the development and commercialization of human prescription pharmaceuticals for managing neglected gastrointestinal symptoms across various complicated disease states.

YTD Price Performance: -57.74%

Average Trading Volume: 90,591

Technical Sentiment Signal: Buy

Current Market Cap: $7.19M

Find detailed analytics on JAGX stock on TipRanks’ Stock Analysis page.